title: Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck.
abstract: OBJECTIVE
  The identification of a reliable circulating tumor marker in squamous cell carcinoma of the head and neck (SCCHN) could assist in diagnosis and monitoring response to therapy.
  
  
  OBJECTIVE
  The aim of this study was to investigate the effectiveness of the serum tumor markers CYFRA 21-1, TPA-M, SCCA, and CEA.
  
  
  METHODS
  Serum levels of CYFRA 21-1, TPA-M, SCCA, and CEA were measured in 136 patients with a histologically proven SCCHN before and after treatment and in 125 healthy subjects, as controls. We evaluated the sensitivity and specificity of these tumor markers and to correlate their levels with tumor staging, grading, or performance status.
  
  
  RESULTS
  The study showed that none of the above markers presented satisfactory specificity and sensitivity in early diagnosis. In comparison with the other markers, TPA-M was the most effective of all markers and indicated a positive correlation with the grade of differentiation and nodal status. A remarkable correlation between high levels of TPA-M and CYFRA 21-1 in advanced stages (III, IV) of cancer has been shown.
  
  
  CONCLUSIONS
  All the tumor markers that were studied have significant limitations in the early diagnosis of cancer, but TPA-M and CYFRA 21-1 may have a role in monitoring the success of therapy and follow up of patients with SCCHN.
authors.affiliation: Department of Otolaryngology, University of Athens, Hippokration Hospital, Athens.
authors.forename: D
authors.initials: D
authors.lastname: Kandiloros
authors.forename: A
authors.initials: A
authors.lastname: Eleftheriadou
authors.forename: T
authors.initials: T
authors.lastname: Chalastras
authors.forename: L
authors.initials: L
authors.lastname: Kyriou
authors.forename: I
authors.initials: I
authors.lastname: Yiotakis
authors.forename: E
authors.initials: E
authors.lastname: Ferekidis
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000473:pathology*; D005260:Female; D006258:Head and Neck Neoplasms / Q000097:blood* / Q000473:pathology*; D006801:Humans; D053539:Keratin-19; D007633:Keratins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D015843:Serpins / Q000097:blood; D019396:Tissue Polypeptide Antigen / Q000097:blood
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D053539:Keratin-19; D015843:Serpins; D019396:Tissue Polypeptide Antigen; C102012:antigen CYFRA21.1; C051072:squamous cell carcinoma-related antigen; D007633:Keratins